ES2174864T3 - Nuevos tratamientos que utilizan derivados de fenetilo. - Google Patents

Nuevos tratamientos que utilizan derivados de fenetilo.

Info

Publication number
ES2174864T3
ES2174864T3 ES94304252T ES94304252T ES2174864T3 ES 2174864 T3 ES2174864 T3 ES 2174864T3 ES 94304252 T ES94304252 T ES 94304252T ES 94304252 T ES94304252 T ES 94304252T ES 2174864 T3 ES2174864 T3 ES 2174864T3
Authority
ES
Spain
Prior art keywords
rent
hydrogen
amino
compound
fenetile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94304252T
Other languages
English (en)
Inventor
Richard Leslie Rudolph
Albert Thomas Derivan
Eric Anthony Muth
Gertrude Virginia Upton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22181084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2174864(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of ES2174864T3 publication Critical patent/ES2174864T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA INVENCION SUMINISTRA EL USO DE UN COMPUESTO PARA PREPARAR UN MEDICAMENTO PARA TRATAR LA OBESIDAD, LAS ENFERMEDADES DE ANSIEDAD GENERALIZADA, LAS ENFERMEDADES DE ESTRES POSTRAUMATICOS, LOS DESORDENES DISFORICOS DE LA ULTIMA FASE LUTEAL (SINDROME PREMESTRUAL), DESORDENES DE FALTA DE ATENCION, CON O SIN HIPERACTIVIDAD, EL SINDROME DE GILLES DE LA TOURETTE, LA BULIMIA NERVIOSA O EL SINDROME DE SHY DRAGER. EL COMPUESTO ES UN AMINO DE HIDROXICICLOALCANOFENOETIL DE LA SIGUIENTE FORMULA ESTRUCTURAL: EN LA CUAL A ES UNA MOLECULA DE LA FORMULA: EN LA QUE LA LINEA PUNTEADA REPRESENTA UNA INSATURACION OPCIONAL; R1 ES HIDROGENO O ALQUIL; R2 ES ALQUIL; R4 ES HIDROGENO, ALQUIL, FORMIL O ALCANOIL; R5 Y R6 SON INDEPENDIENTEMENTE HIDROGENO, HIDROXIL, ALQUIL, ALCOXIDO, ALCANOILOXIDO, CIANO, NITRO, ALQUILMERCAPTO, AMINO, ALQUILAMINO, DIALQUILAMINO, ALCANOILAMINO, HALO, TRIFLUOROMETIL O TOMADAS JUNTAS DIOXIDO DE METILENO; R7 ES HIDROGENO O ALQUIL; Y N ES 0, 1, 2, 3 O 4; ASIMISMO SE PRESENTAN LAS SALES FARMACOLOGICAMENTE ACEPTABLES DEL COMPUESTO.
ES94304252T 1993-06-28 1994-06-13 Nuevos tratamientos que utilizan derivados de fenetilo. Expired - Lifetime ES2174864T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8384893A 1993-06-28 1993-06-28

Publications (1)

Publication Number Publication Date
ES2174864T3 true ES2174864T3 (es) 2002-11-16

Family

ID=22181084

Family Applications (3)

Application Number Title Priority Date Filing Date
ES01115854T Expired - Lifetime ES2273764T3 (es) 1993-06-28 1994-06-13 Nuevos tratamientos que utilizan derivados de fenetilamina.
ES06017469T Expired - Lifetime ES2304041T3 (es) 1993-06-28 1994-06-13 Nuevos tratamientos que utilizan derivados de fenetilamina.
ES94304252T Expired - Lifetime ES2174864T3 (es) 1993-06-28 1994-06-13 Nuevos tratamientos que utilizan derivados de fenetilo.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES01115854T Expired - Lifetime ES2273764T3 (es) 1993-06-28 1994-06-13 Nuevos tratamientos que utilizan derivados de fenetilamina.
ES06017469T Expired - Lifetime ES2304041T3 (es) 1993-06-28 1994-06-13 Nuevos tratamientos que utilizan derivados de fenetilamina.

Country Status (16)

Country Link
US (8) US5916923A (es)
EP (3) EP1153603B1 (es)
JP (2) JPH0789851A (es)
KR (1) KR100342762B1 (es)
AT (3) ATE392893T1 (es)
AU (2) AU6592994A (es)
CA (1) CA2126305C (es)
CY (1) CY2315B1 (es)
DE (3) DE69429895T2 (es)
DK (3) DK1153603T3 (es)
ES (3) ES2273764T3 (es)
HK (1) HK1038880B (es)
LV (1) LV12881B (es)
PT (3) PT1738753E (es)
PY (1) PY0101636A (es)
SG (1) SG47711A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
SG49680A1 (en) * 1994-02-14 1998-06-15 American Home Prod Medicament for the inducement of cognition enhancement
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
EP1331003B1 (en) * 1996-03-25 2015-08-26 Wyeth LLC Extended release formulation containing venlafaxine
JP2002520353A (ja) * 1998-07-16 2002-07-09 マサチューセッツ インスティテュート オブ テクノロジー ストレスの処置のための組成物
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
WO2000059851A1 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
US7291646B2 (en) 1999-11-24 2007-11-06 Wyeth Ethers of O-desmethyl venlafaxine
TR200402408T4 (tr) * 1999-12-30 2004-12-21 H. Lundbeck A/S 4-fenil-1-piperazinil,-piperidinil ve-tetrahidropiridil türevleri
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
FR2807753B1 (fr) * 2000-04-13 2002-06-07 Adir Nouveaux derives d'heterocycloalkylbenzocyclobutane et d'heteroarylbenzocyclobutane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2002250058B2 (en) † 2001-02-12 2007-08-16 Wyeth Llc Novel succinate salt of O-desmethyl-venlafaxine
KR100421508B1 (ko) * 2001-08-07 2004-03-09 김정한 항균 및 항진균 활성을 갖는 신규한 펜에틸아민 유도체와이의 염
EP1451145A1 (en) * 2001-12-05 2004-09-01 Wyeth Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
WO2003082805A1 (en) 2002-03-28 2003-10-09 Synthon B.V. Low water-soluble venlafaxine salts
AR039165A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Venlafaxina base
AR039162A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Formulaciones de venlafaxina de liberacion extendida
EP1485344A1 (en) 2002-03-28 2004-12-15 Synthon B.V. Venlafaxine besylate
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
EP1572160A2 (en) * 2002-11-28 2005-09-14 Themis Laboratories Private Limited Process for manufacturing sustained release microbeads containing venlafaxine hci
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
WO2004075902A1 (en) * 2003-02-28 2004-09-10 Amedis Pharmaceuticals Ltd. Use of silicon derivatives of venlafaxine for the treatment or prevention of psoriasis or panic disorder
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
US20050226923A1 (en) * 2004-04-07 2005-10-13 Gassert Chad M Venlafaxine compositions in the form of microtablets
RU2281788C2 (ru) * 2004-04-19 2006-08-20 Николай Иванович Косенков Способ ультрапарадоксальной психотерапии в лечении психосоматических заболеваний и измененных функциональных состояний человека
RU2276999C2 (ru) * 2004-05-06 2006-05-27 Анатолий Викторович Осницкий Метод коррекции психических состояний и лечения невротических расстройств и патологических зависимостей "интегрально-синергетическая психотерапия"
RU2270036C1 (ru) * 2004-07-14 2006-02-20 Государственное учреждение "Нижегородский научно-исследовательский институт травматологии и ортопедии Министерства здравоохранения Российской Федерации" Способ коррекции психоэмоциональных и психосоматических расстройств у детей с термической травмой
US7776358B2 (en) * 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
RU2273498C1 (ru) * 2004-08-04 2006-04-10 Анатолий Анатолиевич Чумаченко Способ "табу" лечения зависимых форм поведения
RU2272657C1 (ru) * 2005-01-19 2006-03-27 Ирина Анатольевна Нелаева Способ информационно-трансового кодирования в лечении алкоголизма
US20060228413A1 (en) * 2005-02-28 2006-10-12 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
JP2008538572A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
AR054347A1 (es) * 2005-04-22 2007-06-20 Wyeth Corp Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
MX2007013179A (es) * 2005-04-22 2008-01-16 Wyeth Corp Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
JP2008538573A (ja) * 2005-04-22 2008-10-30 ワイス ベンゾフラニルアルカナミン誘導体およびその５−ｈｔ２ｃアゴニストとしての使用
EP1871356A1 (en) * 2005-04-22 2008-01-02 Wyeth a Corporation of the State of Delaware Dihydrobenzofuran derivatives and uses thereof
EP1824815A2 (en) * 2005-10-19 2007-08-29 Teva Pharmaceutical Industries Ltd. Process for the preparation of highly pure 1-[2-dimethylamino-(4-methoxyphenyl) ethyl]cyclohexanol hydrochloride
PT1954669E (pt) * 2005-12-01 2015-10-23 Auspex Pharmaceuticals Inc Feniletilaminas substituídas com actividade serotoninérgica e/ou norepinefrinérgica
CN101321741A (zh) 2005-12-05 2008-12-10 惠氏公司 选择性合成经取代1-(2-氨基-1-苯基-乙基)-环己醇的对映异构体的方法
RU2008135326A (ru) * 2006-03-24 2010-04-27 Вайет (Us) Терапевтические композиции для лечения депрессии
US20080027072A1 (en) * 2006-04-20 2008-01-31 Ampla Pharmaceuticals, Inc. Potentiation of MC4 receptor activity
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
CL2007003067A1 (es) * 2006-10-25 2008-04-11 Wyeth Corp Compuestos derivados de ortodesmetilvenlafaxina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos del sistema nervioso central.
LT2125698T (lt) 2007-03-15 2016-10-10 Auspex Pharmaceuticals, Inc. Deuterintas d9-venlafaksinas
WO2009023820A1 (en) * 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination
WO2009065845A1 (en) * 2007-11-20 2009-05-28 Neurosearch A/S A method for treating over-eating disorders
KR100965527B1 (ko) * 2008-05-08 2010-06-23 제일약품주식회사 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물
CZ301820B6 (cs) * 2009-02-06 2010-06-30 Zentiva, K.S. Nové soli desvenlafaxinu a zpusob jejich prípravy
US20140118944A1 (en) * 2012-10-25 2014-05-01 Inhon International Co. Ltd. Electronic device
KR102132304B1 (ko) 2020-02-17 2020-07-09 박광순 접이식 유아용 비데
RU2741226C1 (ru) * 2020-09-08 2021-01-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) Способ профилактики агрессии лиц с интернет-зависимостью

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017637A (en) * 1973-03-26 1977-04-12 American Home Products Corporation Benzylamine analgesics
US3894051A (en) * 1973-07-05 1975-07-08 Colgate Palmolive Co N-methylenedioxyphenylalkyl)-{62 -(alkyl)-disubstituted phenethylamines
US4435449A (en) * 1981-05-14 1984-03-06 Burroughs Wellcome Co. Treatment of minimal brain dysfunction (MBD)
US4824868A (en) * 1982-09-07 1989-04-25 Ciba-Geigy Corporation Propylamine derivatives useful for the treatment of dementia
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
AU566673B2 (en) * 1983-09-15 1987-10-29 F. Hoffmann-La Roche Ag Phenethylamine derivatives
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4611078A (en) * 1983-10-26 1986-09-09 American Home Products Corporation Substituted phenylacetonitriles
US4609758A (en) * 1985-05-09 1986-09-02 American Home Products Corporation Phenoxyethylamine derivatives
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
ATE175358T1 (de) * 1987-10-22 1999-01-15 Massachusetts Inst Technology Behandlung des prämenstruellen oder späten lutealsphase-syndroms
US4996235A (en) * 1987-11-25 1991-02-26 Eli Lilly And Company 3,4-diphenylbutanamines
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5006525A (en) * 1989-07-24 1991-04-09 Eli Lilly And Company Dopamine agonists method
US5057515A (en) * 1989-07-24 1991-10-15 Eli Lilly And Company Method for agonizing a dopamine receptor
FI910897L (fi) * 1990-02-28 1991-08-29 Lilly Co Eli Foerbaettringar roerande (s)-norfluoxetin.
EP0449562A3 (en) * 1990-03-29 1992-03-18 Eli Lilly And Company Use of r-fluoxetine as selective serotonin ic-receptor ligands
AU1373692A (en) * 1991-11-15 1993-06-15 Sepracor, Inc. Methods and compositions utilizing pure s(+) isomer fluoxetine
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
TW460478B (en) * 1997-08-15 2001-10-21 Chugai Pharmaceutical Co Ltd Phenethylamine derivatives

Also Published As

Publication number Publication date
EP1738753B1 (en) 2008-04-23
US20030181517A1 (en) 2003-09-25
CA2126305A1 (en) 1994-12-29
HK1038880A1 (en) 2002-04-04
CA2126305C (en) 2006-10-17
DE69435095D1 (de) 2008-06-05
US6730706B2 (en) 2004-05-04
US20020052405A1 (en) 2002-05-02
PT639374E (pt) 2002-07-31
US20040110829A1 (en) 2004-06-10
EP0639374B1 (en) 2002-02-20
CY2315B1 (en) 2003-11-14
DK1153603T3 (da) 2006-12-18
US20080176950A1 (en) 2008-07-24
AU5831298A (en) 1998-05-21
US20010012855A1 (en) 2001-08-09
ATE213407T1 (de) 2002-03-15
DE69435095T2 (de) 2009-07-02
ATE342715T1 (de) 2006-11-15
EP1153603A2 (en) 2001-11-14
ES2304041T3 (es) 2008-09-01
LV12881B (en) 2002-11-20
ATE392893T1 (de) 2008-05-15
AU6592994A (en) 1995-01-05
EP1153603B1 (en) 2006-10-18
KR950000139A (ko) 1995-01-03
JPH0789851A (ja) 1995-04-04
EP1738753A3 (en) 2007-01-31
PY0101636A (es) 2001-12-03
EP1738753A2 (en) 2007-01-03
DE69434872D1 (de) 2006-11-30
DE69434872T2 (de) 2007-04-05
PT1153603E (pt) 2007-01-31
EP0639374A2 (en) 1995-02-22
ES2273764T3 (es) 2007-05-16
EP0639374A3 (en) 1995-08-02
EP1153603A3 (en) 2003-05-21
US6465524B2 (en) 2002-10-15
PT1738753E (pt) 2008-06-19
KR100342762B1 (ko) 2002-11-18
DE69429895T2 (de) 2002-08-29
SG47711A1 (en) 1998-04-17
US6444708B2 (en) 2002-09-03
DK0639374T3 (da) 2002-05-06
DE69429895D1 (de) 2002-03-28
JP2006117689A (ja) 2006-05-11
US5916923A (en) 1999-06-29
US20010053799A1 (en) 2001-12-20
DK1738753T3 (da) 2008-08-11
US6555586B2 (en) 2003-04-29
US6310101B1 (en) 2001-10-30
HK1038880B (en) 2006-12-22

Similar Documents

Publication Publication Date Title
ES2174864T3 (es) Nuevos tratamientos que utilizan derivados de fenetilo.
UY28150A1 (es) Agentes terapeuticos
ECSP941122A (es) Derivados de 5-arilindoles
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
PA8493701A1 (es) Compuestos para tratar la obesidad
ES2163090T3 (es) Uso de toxina botulinica para tratar la cefalea tensional.
UY28376A1 (es) Agentes terapéuticos
AR025111A1 (es) Metodos y composiciones para tratar trastornos de ansiedad generalizada
EA200300323A1 (ru) ПРОИЗВОДНЫЕ ГУАНИДИНОБЕНЗАМИДА (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ ОПОСРЕДОВАННОГО mc4-r ЗАБОЛЕВАНИЯ (ВАРИАНТЫ)
MX9301847A (es) Aminas biciclicas-heterociclicas farmaceuticamente activas
ATE316076T1 (de) Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
AR021893A1 (es) Compuesto de 2-fenil-1-(3,4-dihidroxi-5-nitrofenil)-1-etanona sustituida , su uso para la manufactura de un medicamento en el tratamiento de algunos trastornos del sistema nervioso central y periférico y composiciones farmacéuticas que las contienen
AR013078A1 (es) Derivados de tetrahidroisoquinoleina, una sal de los mismos, procedimiento para su preparacion, composicion farmaceutica que los comprende y el uso de losmismos en la preparacion de un medicamento.
NO20014529D0 (no) Tetrahydropyranderivater og deres anvendelse som terapautiske midler
AR002711A1 (es) Un compuesto de 2-carboxindol-3-substituido,un proceso para su preparacion, un nuevo compuesto intermediario para dicho proceso, el uso del compuesto parala fabricacion de un agente terapeutico y una composicion farmaceutica que comprende dicho compuesto.
AR007088A1 (es) 2,4-diaminopirimidinas sustituidas, compuestos intermedios utilizados en su preparacion, procedimiento para la preparacion de dichas 2,4-diaminopirimidinas sustituidas, medicamentos que las contienen y empleos de dichas pirimidinas
ES2176321T3 (es) Derivados tetrasustituidos del imidazol, su procedimiento de preparacion, su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
ES2058596T3 (es) Empleo de derivados de l-carnitina en el tratamiento terapeutico de alteraciones degenerativas del sistema nervioso.
DK0526313T3 (da) Nye ureaderivater, deres fremstilling og terapeutiske anvendelse
DK1037629T3 (da) Kombination af et retinsyremetabolismeblokerende middel og en tocopherol
DK0728138T3 (da) Anthracyclinderivater
NO943372L (no) Behandling av migrene
PE20011260A1 (es) Derivados de sulfonamida

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 639374

Country of ref document: ES